Cytochrome Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 04-12-2024
- Paid Up Capital ₹ 0.49 M
as on 04-12-2024
- Company Age 15 Year, 2 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.00 M
as on 04-12-2024
- Revenue 170.44%
(FY 2022)
- Profit -312.11%
(FY 2022)
- Ebitda 139.45%
(FY 2022)
- Net Worth -46.56%
(FY 2022)
- Total Assets -36.13%
(FY 2022)
About Cytochrome Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.49 M.
The company currently has active open charges totaling ₹1.00 M.
Ashutosh Thakur and Tulika Thakur serve as directors at the Company.
- CIN/LLPIN
U24232DL2009PTC195361
- Company No.
195361
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Oct 2009
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Cytochrome Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashutosh Thakur  | Managing Director | 20-Oct-2009 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Tulika Thakur | Director | 04-Apr-2017 | Current |
Financial Performance of Cytochrome Life Sciences.
Cytochrome Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 170.44% increase. The company also saw a substantial fall in profitability, with a 312.11% decrease in profit. The company's net worth observed a substantial decline by a decrease of 46.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cytochrome Life Sciences?
In 2022, Cytochrome Life Sciences had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 14 Oct 2016 | ₹1.00 M | Open |
How Many Employees Work at Cytochrome Life Sciences?
Cytochrome Life Sciences has a workforce of 12 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cytochrome Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cytochrome Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
